Molnupiravir, an antiviral medication for COVID-19 infections, and a pattern of mutations in the SARS-CoV-2 virus have been linked, according to research from the Francis Crick Institute, the University of Cambridge, Imperial College London, the University of Liverpool, the University of Cap
Researchers from the Salk Institute and the National Institutes of Health have identified the molecular pathways by which the human immunodeficiency virus (HIV) develops resistance to dolutegravir, one of the most potent antiviral medications now being used in clinical use to treat HIV.
Researchers from the Salk Institute and the National Institutes of Health have identified the molecular pathways by which the human immunodeficiency virus (HIV) develops resistance to dolutegravir, one of the most potent antiviral medications now being used in clinical use to treat HIV.
When HIV patients get antiviral medication (ART), their viral levels are reduced to the point that a conventional blood test cannot detect the virus. However, once ART is discontinued, detectable HIV resurfaces, infecting new cells. The cells that release the virus to re-ignite the infection
Mumbai (Maharashtra) [India], November 23 (ANI/PRNewswire): The oral antiviral medication Favipiravir, that prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with mild to moderate COVID-19.
Washington D.C [USA], Jun 11 (ANI): A team of researchers is calling for the discouragement of decision-making for antiviral medication based on rapid influenza antigen test (RIAT) results.